ES2086526T3 - Aplicacion medicinal de m-csf. - Google Patents

Aplicacion medicinal de m-csf.

Info

Publication number
ES2086526T3
ES2086526T3 ES91900912T ES91900912T ES2086526T3 ES 2086526 T3 ES2086526 T3 ES 2086526T3 ES 91900912 T ES91900912 T ES 91900912T ES 91900912 T ES91900912 T ES 91900912T ES 2086526 T3 ES2086526 T3 ES 2086526T3
Authority
ES
Spain
Prior art keywords
csf
medical application
allergies
recombinant
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91900912T
Other languages
English (en)
Inventor
Gideon Strassmann
Satoru Nakai
Masayuki Takahashi
Hiroyuki Ichikawa
Yoshikatsu Hirai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2086526T3 publication Critical patent/ES2086526T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

APLICACION MEDICINAL DE M-CSF, SOBRE TODO UN METODO Y DROGA PARA EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS Y ALERGIAS CON M-CSF NATURAL, M-CSF RECOMBINANTE O UN DERIVADO DEL MISMO.
ES91900912T 1989-12-13 1990-12-12 Aplicacion medicinal de m-csf. Expired - Lifetime ES2086526T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP32351889 1989-12-13
US51775290A 1990-05-02 1990-05-02
PCT/JP1990/001629 WO1991008754A1 (fr) 1989-12-13 1990-12-12 Application medicinale de m-csf
AU77379/91A AU637909B2 (en) 1989-12-13 1991-05-28 Medical uses of m-csf

Publications (1)

Publication Number Publication Date
ES2086526T3 true ES2086526T3 (es) 1996-07-01

Family

ID=27156236

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91900912T Expired - Lifetime ES2086526T3 (es) 1989-12-13 1990-12-12 Aplicacion medicinal de m-csf.

Country Status (7)

Country Link
EP (1) EP0456842B1 (es)
JP (1) JPH0653673B2 (es)
AU (1) AU637909B2 (es)
DE (1) DE69026077T2 (es)
DK (1) DK0456842T3 (es)
ES (1) ES2086526T3 (es)
WO (1) WO1991008754A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU676227B2 (en) * 1993-01-22 1997-03-06 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Therapeutic agent for NIDDM
EP0663211A4 (en) * 1993-03-17 1997-07-09 Otsuka Pharma Co Ltd AGENT FOR PREVENTION AND TREATMENT OF DIGESTIVE APPARATUS MUCOUS DISORDERS.
WO1995009611A2 (en) * 1993-10-06 1995-04-13 Amgen Inc. Stable protein: phospholipid compositions and methods
IT1276213B1 (it) * 1995-10-06 1997-10-27 Mendes Srl Composizioni dermatologiche e cosmetiche atte all'applicazione topica, ad effetto modulante sulle ceramidi endogene dell'epidermide
HUP9903292A3 (en) * 1996-05-31 2000-08-28 Sankyo Co Use of substances improving insulin resistance for production of remedies for autoimmune diseases
US20140030218A1 (en) * 2011-01-05 2014-01-30 Imperial Innovations Limited Treatment And Screening
JP6251516B2 (ja) * 2012-10-24 2017-12-20 株式会社ダイセル 皮膚感作性物質の検出方法
CN114252617A (zh) * 2020-09-21 2022-03-29 张曼 尿液巨噬细胞集落刺激因子-1及其多肽片段在过敏性疾病中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2583770B2 (ja) * 1986-09-17 1997-02-19 大塚製薬株式会社 遺伝子
AU625807B2 (en) * 1987-09-22 1992-07-16 Novartis Vaccines And Diagnostics, Inc. Uses of recombinant colony stimulating factor-1
US4961926A (en) * 1987-11-19 1990-10-09 Sloan-Kettering Institute For Cancer Research Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor
JPH0610137B2 (ja) * 1988-02-29 1994-02-09 新技術事業団 ヒト単球−マクロファージコロニー刺激因子を有効成分とする造血器疾患治療剤
US5021239A (en) * 1988-03-21 1991-06-04 Genetics Institute, Inc. Use of M-CSF to improve lipoprotein cholesterol profiles

Also Published As

Publication number Publication date
DK0456842T3 (da) 1996-04-15
WO1991008754A1 (fr) 1991-06-27
JPH0653673B2 (ja) 1994-07-20
EP0456842A1 (en) 1991-11-21
AU637909B2 (en) 1993-06-10
EP0456842B1 (en) 1996-03-20
DE69026077T2 (de) 1996-10-17
AU7737991A (en) 1992-12-17
DE69026077D1 (de) 1996-04-25
EP0456842A4 (en) 1992-07-22

Similar Documents

Publication Publication Date Title
ATE82121T1 (de) Arzneimittel fuer die therapeutische behandlung von alopezie.
FI902583A7 (fi) Suonensisäinen lääkkeenanto- ja laajennuskatetri
CO4290346A1 (es) Formas de dosificacion de liberacion controlada de azitromicina
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
NO883896L (no) Fremgangsmaate til fremstilling av konjugater av cytokinermed menneskelig immunglobulin.
DE3776946D1 (de) Nasale verabreichung von arzneimitteln.
HUT63564A (en) Medical preparatives, method for producing them and their applications as analgetic and/or febrifuge in human and veterinary medicine
NO954996L (no) Anvendelse av nona- og dekapeptider for fremstilling av et legemiddel for behandling av AIDS
NO881657L (no) Medisinske preparater paa grunnlag av oelmaskekstrakt, fremgangsmaate for fremstilling derav samt anvendelse av oelmaskekstrakt for fremstilling av kosmetiske preparater og et spesielt oelmaskekstrakt.
ATE122880T1 (de) Mehrfach teilbare tablettenstruktur.
DE69327432D1 (de) Heilmittel für wunden und hämorrhoiden
DE69426334D1 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
DE69200711D1 (de) Pharmazeutische Zusammensetzungen enthaltend Fluticasonpropionat und Oxikonazol oder dessen Salz zur lokalen Anwendung.
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
ES2086526T3 (es) Aplicacion medicinal de m-csf.
DK561089D0 (da) Anvendelse af lactamimider til fremstilling af laegemidler
DE68926746D1 (de) Auf phosphozucker basierende antientzündliche und/oder immunitätsunterdrückende arzneimittel
DK34687A (da) Laegemiddel til nasal anvendelse, dets fremstilling og anvendelse
DK0559145T3 (da) Lægemiddel til truende abort
FI950649L (fi) Substituoidut sykloheksanoliesterit, niiden käyttö sairauksien hoitamiseksi ja farmaseuttiset valmisteet
NO953003L (no) Anvendelse av ifenprodil og diastereoisomerer derav for fremstilling av medisinske preparater
SE9101341D0 (sv) New medicinal use
ES2161809T3 (es) Uso de factor proliferativo osteoblastico.
SE8802040D0 (sv) New use
FI930097A7 (fi) Annostusmuoto lääkeaineen antamiseksi vuorokausiterapian toteuttamista varten

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 456842

Country of ref document: ES